What is HC Wainwright’s Forecast for CANF FY2026 Earnings?

Can-Fite BioPharma Ltd. (NYSE:CANF) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Can-Fite BioPharma in a research note issued on Tuesday, May 12th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($1.04) per share for the year. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s FY2027 earnings at ($0.26) EPS.

Separately, D. Boral Capital raised Can-Fite BioPharma from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Can-Fite BioPharma Trading Up 7.4%

Shares of NYSE CANF opened at $3.64 on Thursday. The stock has a market cap of $2.38 million, a P/E ratio of -2.03 and a beta of 1.09. Can-Fite BioPharma has a twelve month low of $2.83 and a twelve month high of $23.40. The stock has a 50 day moving average of $3.39 and a two-hundred day moving average of $4.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Can-Fite BioPharma during the fourth quarter worth about $41,000. Sabby Management LLC lifted its stake in shares of Can-Fite BioPharma by 80.3% during the third quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after buying an additional 626,306 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Can-Fite BioPharma by 42.4% during the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after buying an additional 11,388 shares during the period. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).